Moricizine | CAS#31883-05-3 (free base) | antiarrhythmia agent

MedKoo Cat#: 318290 | Name: Moricizine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Moricizine is an antiarrhythmia agent used primarily for ventricular rhythm disturbances.

Chemical Structure

Moricizine

CAS#31883-05-3 (free base)

Theoretical Analysis

MedKoo Cat#: 318290

Name: Moricizine

CAS#: 31883-05-3 (free base)

Chemical Formula: C22H25N3O4S

Exact Mass: 427.1566

Molecular Weight: 427.52

Elemental Analysis: C, 61.81; H, 5.89; N, 9.83; O, 14.97; S, 7.50

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

29560-58-5 (HCl) 31883-05-3 (free base)

Synonym

Moricizine, EN-313, Moracizine, Ethmozine

IUPAC/Chemical Name

ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate

InChi Key

FUBVWMNBEHXPSU-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27)

SMILES Code

O=C(OCC)NC(C=C1N2C(CCN3CCOCC3)=O)=CC=C1SC4=C2C=CC=C4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Moricizine is an antiarrhythmia agent used primarily for ventricular rhythm disturbances.

In vitro activity:

Here, the effect of moricizine (10 μM) was examined in vitro on perfused right atrial preparation, where it completely reproduced all the previously observed phenomena and disturbed electrical coupling between the working cardiomyocytes in 35.3±3.4 min, which arrested generation of action potentials. Thus, moricizine disturbed conduction between the working atrial cardiomyocytes without affecting the pacemaker activity. Reference: Bull Exp Biol Med. 2018 Jul;165(3):351-355. https://pubmed.ncbi.nlm.nih.gov/30003421/

In vivo activity:

Angiotensin II (Ang II) was induced in C57Bl/6 mice (male wild-type) for 4 weeks to increase the susceptibility of AF (atrial fibrillation), and acetylcholine-calcium chloride was used to induce AF. The results showed that moricizine significantly inhibited Ang II-mediated atrial enlargement and reduced AF vulnerability. In addition, moricizine reduced the Ang II-induced upregulation of phosphorylated calcium/calmodulin-dependent protein kinase-II (p-CaMKII) in both the left and right atria. In HL-1 cells, moricizine also reduced the upregulation of p-CaMKII with Ang II and ATX II intervention, respectively. Reference: J Thorac Dis. 2022 Jun;14(6):2187-2200. https://pubmed.ncbi.nlm.nih.gov/35813708/

Preparing Stock Solutions

The following data is based on the product molecular weight 427.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Abalakov GA, Sutyagin PV. Moricizine (Ethmozine) Can Break Electrical Coupling between Rat Right Atrial Working Cardiomyocytes In Vitro. Bull Exp Biol Med. 2018 Jul;165(3):351-355. doi: 10.1007/s10517-018-4168-9. Epub 2018 Jul 12. PMID: 30003421. 2. Ahmmed GU, Hisatome I, Kurata Y, Makita N, Tanaka Y, Tanaka H, Okamura T, Sonoyama K, Furuse Y, Kato M, Yamamoto Y, Ogura K, Shimoyama M, Miake J, Sasaki N, Ogino K, Igawa O, Yoshida A, Shigemasa C. Analysis of moricizine block of sodium current in isolated guinea-pig atrial myocytes. Atrioventricular difference of moricizine block. Vascul Pharmacol. 2002 Mar;38(3):131-41. doi: 10.1016/s1537-1891(02)00213-6. PMID: 12402511. 3. Zou T, Chen Q, Chen C, Liu G, Ling Y, Pang Y, Xu Y, Cheng K, Zhu W, Wang RX, Qian LL, Ge J. Moricizine prevents atrial fibrillation by late sodium current inhibition in atrial myocytes. J Thorac Dis. 2022 Jun;14(6):2187-2200. doi: 10.21037/jtd-22-534. PMID: 35813708; PMCID: PMC9264100. 4. Konishi H, Morita K, Minouchi T, Yamaji A. Moricizine, an antiarrhythmic agent, as a potent inhibitor of hepatic microsomal CYP1A. Pharmacology. 2002 Dec;66(4):190-8. doi: 10.1159/000065533. PMID: 12393941.

In vitro protocol:

In vivo protocol:

1. Zou T, Chen Q, Chen C, Liu G, Ling Y, Pang Y, Xu Y, Cheng K, Zhu W, Wang RX, Qian LL, Ge J. Moricizine prevents atrial fibrillation by late sodium current inhibition in atrial myocytes. J Thorac Dis. 2022 Jun;14(6):2187-2200. doi: 10.21037/jtd-22-534. PMID: 35813708; PMCID: PMC9264100. 2. Konishi H, Morita K, Minouchi T, Yamaji A. Moricizine, an antiarrhythmic agent, as a potent inhibitor of hepatic microsomal CYP1A. Pharmacology. 2002 Dec;66(4):190-8. doi: 10.1159/000065533. PMID: 12393941.

1: Clyne CA, Estes NA 3rd, Wang PJ. Moricizine. N Engl J Med. 1992 Jul 23;327(4):255-60. Review. PubMed PMID: 1614466. 2: Grubb BP. Moricizine: a new agent for the treatment of ventricular arrhythmias. Am J Med Sci. 1991 Jun;301(6):398-401. Review. PubMed PMID: 2039027. 3: Mann HJ. Moricizine: a new class I antiarrhythmic. Clin Pharm. 1990 Nov;9(11):842-52. Review. PubMed PMID: 2272151. 4: Carnes CA, Coyle JD. Moricizine: a novel antiarrhythmic agent. DICP. 1990 Jul-Aug;24(7-8):745-53. Review. PubMed PMID: 2197817. 5: Kennedy HL. Noncardiac adverse effects and organ toxicity of moricizine during short- and long-term studies. Am J Cardiol. 1990 Feb 20;65(8):47D-50D. Review. PubMed PMID: 2407091. 6: Bigger JT Jr. Cardiac electrophysiologic effects of moricizine hydrochloride. Am J Cardiol. 1990 Feb 20;65(8):15D-20D; discussion 68D-71D. Review. PubMed PMID: 2407089. 7: Anderson JL. Comparisons of efficacy and tolerance of moricizine with other antiarrhythmic agents in the treatment of chronic ventricular arrhythmias. Am J Cardiol. 1990 Feb 20;65(8):32D-40D. Review. PubMed PMID: 2106254. 8: Snyder DW. Class IB antiarrhythmic drugs: tocainide, mexiletine, and moricizine. J La State Med Soc. 1989 May;141(5):21-5. Review. PubMed PMID: 2499645. 9: Kennedy HL, Wood AJ, MacFarland RT. Drug interactions with Ethmozine (moricizine HCl). Am J Cardiol. 1987 Oct 16;60(11):79F-82F. Review. PubMed PMID: 3310590. 10: Rosenshtraukh LV, Anyukhovsky EP, Nesterenko VV, Undrovinas AI, Shugushev KKh, Portnoy VF, Burnashev NA. Electrophysiologic aspects of moricizine HCl. Am J Cardiol. 1987 Oct 16;60(11):27F-34F. Review. PubMed PMID: 3310582. 11: Vanerio G, Maloney JD. Moricizine: pharmacodynamic, pharmacokinetic, and therapeutic profile of a new antiarrhythmic. Cleve Clin J Med. 1992 Jan-Feb;59(1):79-86. Review. PubMed PMID: 1551218. 12: Guo W, Zhu J. [Advances in the research on moricizine and its uses in anti-arrhythmia]. Zhonghua Xin Xue Guan Bing Za Zhi. 1991 Dec;19(6):392-5. Review. Chinese. PubMed PMID: 1821360. 13: Fauchier JP, Babuty D, Rouesnel P, Cosnay P, Estepo J. [Comparison of the efficacy of moricizine and disopyramide in the treatment of ventricular extrasystoles]. Arch Mal Coeur Vaiss. 1991 Apr;84(4):553-60. Review. French. PubMed PMID: 1712193. 14: Fitton A, Buckley MT. Moricizine. A review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias. Drugs. 1990 Jul;40(1):138-67. Review. PubMed PMID: 2202581. 15: Podrid PJ, Beau SL. Antiarrhythmic drug therapy for congestive heart failure with focus on moricizine. Am J Cardiol. 1990 Feb 20;65(8):56D-64D; discussion 68D-71D. Review. PubMed PMID: 2407092. 16: Siddoway LA, Schwartz SL, Barbey JT, Woosley RL. Clinical pharmacokinetics of moricizine. Am J Cardiol. 1990 Feb 20;65(8):21D-25D; discussion 68D-71D. Review. PubMed PMID: 2407090. 17: Mahler SA, Borland RM. Clinical development of moricizine as an antiarrhythmic agent. Am J Cardiol. 1990 Feb 20;65(8):11D-14D; discussion 68D-71D. Review. PubMed PMID: 2407088. 18: Horowitz LN. Efficacy of moricizine in malignant ventricular arrhythmias. Am J Cardiol. 1990 Feb 20;65(8):41D-46D; discussion 68D-71D. Review. PubMed PMID: 1689535. 19: Morganroth J, Pratt CM, Kennedy HL, Singh SN, Platt ML, Baker BJ, Mason DT. Efficacy and tolerance of Ethmozine (moricizine HCl) in placebo-controlled trials. Am J Cardiol. 1987 Oct 16;60(11):48F-51F. Review. PubMed PMID: 3310585. 20: Woosley RL, Morganroth J, Fogoros RN, McMahon FG, Humphries JO, Mason DT, Williams RL. Pharmacokinetics of moricizine HCl. Am J Cardiol. 1987 Oct 16;60(11):35F-39F. Review. PubMed PMID: 3310583.